» Authors » Michel Flesch

Michel Flesch

Explore the profile of Michel Flesch including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 705
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Andre T, Tournigand C, Achille E, Tubiana-Mathieu N, Lledo G, Raoul Y, et al.
Bull Cancer . 2006 Feb; 93 Suppl 1:S5-9. PMID: 16483940
Oxaliplatin in combination with 5-fluorouracil/leucovorin (LV5FU) improves the response rate and survival of patients with metastatic colorectal cancer. The objective of the Mosaic study was to evaluate the efficacy of...
12.
Nguyen S, Rebischung C, Van Ongeval J, Flesch M, Bennamoun M, Andre T, et al.
Bull Cancer . 2006 Feb; 93(1):E1-6. PMID: 16455499
Methods: We evaluated the Epitax combination (epirubicin 60 mg/m2 and docetaxel 75 mg/m2, every 3 weeks) in advanced gastric cancer (AGC) as second-line treatment after fluorouracil and platinum in 50...
13.
Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al.
J Clin Oncol . 2006 Jan; 24(3):394-400. PMID: 16421419
Purpose: In metastatic colorectal cancer, a combination of leucovorin (LV) and fluorouracil (FU) with oxaliplatin (FOLFOX) 4 is a standard first-line regimen. The cumulative neurotoxicity of oxaliplatin often requires therapy...
14.
Cercueil J, Ferrant E, Isambert N, Jouve J, Flesch M, Krause D, et al.
Gastroenterol Clin Biol . 2005 Jan; 28(12):1281-3. PMID: 15671939
Although chemoembolization is known to be an effective palliative treatment in hepatocellular carcinoma, it has a limited effect in large tumors. We report the case of a patient with a...
15.
Andre T, Colin P, Louvet C, Gamelin E, Bouche O, Achille E, et al.
J Clin Oncol . 2003 Jul; 21(15):2896-903. PMID: 12885807
Purpose: This randomized, 2 x 2 factorial study compared a semimonthly (LVFU2) with a monthly (FULV) regimen of fluorouracil and leucovorin and 24 versus 36 weeks of each regimen as...